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Clear cell renal cell carcinoma (CCRCC) is the most common origin for metastasis in the thyroid. A 51-year-old woman was
referred to our hospital for a subcarinal lesion. Ten years before, the patient had undergone a nephrectomy for CCRCC. Whole-
body fluorodeoxyglucose positron emission tomography revealed elevated values in the thyroid gland, while the mediastinum was
normal. An endoscopic ultrasonography-guided fine-needle aspiration biopsy of themediastinalmass was consistent with CCRCC,
and this was confirmed after resection. The thyroidectomy specimen also revealed lymphocytic thyroiditis, nodular hyperplasia,
one follicular adenoma, two papillary microcarcinomas, and six foci of metastatic CCRCC involving both thyroid lobes. Curiously
two of the six metastatic foci were located inside two adenomatoid nodules (tumor-in-tumor).Themetastatic cells were positive for
cytokeratins, CD10, epidermal growth factor receptor, and vascular endothelial growth factor receptor 2. No BRAF gene mutations
were found in any of the primary and metastatic lesions. The patient was treated with sunitinib and finally died due to CCRCC
distant metastases 6 years after the thyroidectomy. In CCRCC patients, a particularly prolonged survival rate may be achieved with
the appropriate therapy, in contrast to the ominous prognosis typically found in patients with thyroidmetastases from other origins.
1. Introduction
Renal cancer represents around 3% of adult malignancies
[1]. Clear cell renal cell carcinoma (CCRCC) is the most
frequent histological type, and although the clinical course
of CCRCC is unpredictable, there is a high probability of
late distant metastasis occurring in unusual locations [1–
3]. In fact after radical nephrectomy, long-term monitoring
is necessary because CCRCC may recur many years after
diagnosis [3]. CCRCC remains one of the most lethal of
the major genitourinary malignancies with 30% to 40% of
patients eventually dying from the disease [4]. About 20–
30% of patients with CCRCC have synchronous distant
metastases at the time of primary diagnosis; another 30%
develop metachronous metastases [2]. In autopsy series,
thyroid metastases from CCRCC have been detected in 4-5%
of patients, but those that are clinically significant are a rare
event [2].
In earlier studies cytokine therapy with interferon-alpha
or interleukin-2 (IL-2) was shown to induce objective
responses, although only achieving durable survival rates in
a minority of patients with renal cell carcinoma [5]. Recent




Figure 1: Metastatic renal cell carcinoma. (a and b) Computed tomography showed the renal metastatic mass (arrow) in the mediastinum.
(c) Fine-needle aspiration biopsy guided by endoscopic ultrasonography of the mediastinal tumor revealed clusters of epithelial malignant
cells morphologically fitting with metastatic clear cell renal cell carcinoma (Diff-Quick).
advances in understanding themolecular biology of common
CCRCC have resulted in the development of drugs that target
known molecular pathways involved in cellular proliferation
and neoangiogenesis. Agents, such as axitinib, sunitinib,
bevacizumab, sorafenib, and temsirolimus, have been used in
several clinical settings in the management of metastatic or
recurrent CCRCC [6].
Here, we present a case of recurrent CCRCC, with
metastases to both the mediastinal lymph nodes and the thy-
roid gland 10 years after nephrectomy. Curiously, a peculiar
distribution of metastatic foci inside adenomatoid nodules
(tumor-in-tumor) was found. In addition, a particularly
prolonged survival rate was achieved, in contrast to the
ominous prognosis typically found in patients with thyroid
metastases from other origins.
2. Case Presentation
2.1. Clinical Summary. A 51-year-old Caucasian woman pre-
sented with a 4 cm well-defined hyperdense subcarinal mass
detected during a surveillance computed tomography (CT)
scan (Figures 1(a) and 1(b)). Ten years before, the patient
had been diagnosed as having a CCRCC (nuclear grade 2,
stage pT1bN0M0) and underwent a left nephrectomy with an
adjuvant therapy of IL-2, subcutaneously, in a clinical trial.
There was no history of von Hippel-Lindau syndrome or
other hereditary cancer disorders.
A bronchoscopy showed enlargement of the carina, and a
fine-needle aspiration biopsy (FNAB) guided by endoscopic
ultrasonography revealed clusters of epithelialmalignant cells
with clear cytoplasm morphologically fitting with metastatic
CCRCC (Figure 1(c)). The whole-body fluorodeoxyglucose
positron emission tomography (FDG-PET) was negative in
the mediastinum, but a higher value uptake in the thyroid
gland was present. The patient underwent thoracotomy with
complete excision of the mediastinal lesion; the pathological
examination revealed a metastatic CCRCC. A thyroid gam-
magraphy showed two cold nodules in a multinodular goiter,
and a thyroidectomy was performed in order to rule out a
primary thyroid neoplasm.
One year after the thyroidectomy, a new CT scan
showed multiple pulmonary nodules, a right supraclavicular
adenopathy, and metastasis in the left rhomboid muscle.
Treatment was started with sunitinib 50mg/day, and the
patient remained clinically stable for a 5-year-period but
finally died due to multiple metastases 6 years after the
thyroidectomy.
2.2. Pathological Findings. Histologic examination of the
thyroidectomy specimen showed a lymphocytic thyroidi-
tis, nodular hyperplasia (multinodular goiter), one follic-
ular adenoma, two foci of papillary microcarcinoma, fol-
licular variant, measuring 2 and 4mm, and six foci of
metastatic CCRCC, measuring from 1 to 8mm in diameter,
involving both thyroid lobes (Figures 2 and 3). Curiously,
two foci of CCRCC presented as central lesions inside
hyperplastic adenomatoid nodules of follicular cells (Figures
3(a)–3(f)). In the immunohistochemical study performed
on paraffin sections using a peroxidase-conjugated labeled
dextran polymer (Dako EnVision Peroxidase/DAB; Dako,
Glostrup, Denmark), the papillary microcarcinomas of the
thyroid were positive for cytokeratins (clone AE1/AE3,
ready-to-use, Dako), thyroglobulin (8G7G3/1, dilution 1 : 20;
Dako), thyroid transcription factor-1 (TTF-1, 8G7G3/1,
ready-to-use, Dako), and Hector Battifora mesothelial cell
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Figure 2: Concurrent renal cell carcinoma and thyroid carcinoma. (a)Thyroidectomy specimen showed synchronous foci of metastatic clear
cell renal cell carcinoma (top) and papillary thyroid carcinoma (bottom) (hematoxylin and eosin).The characteristic clear cell cytoplasmof the
renal cell carcinoma (b) and the peculiar nuclear features of papillary thyroid carcinoma (c) are seen at a higher magnification (hematoxylin
and eosin).
(HBME-1, dilution 1 : 200; Dako), with negativity for calci-
tonin (polyclonal, dilution 1 : 5,000; BioGenex, San Ramon,
CA); renal tumor cells showed reactivity for cytokeratins,
CD10 (56C6, ready-to-use, Dako) (Figure 3(c)), epidermal
growth factor receptor (EGFR, EGFR pharmDx, Dako) (Fig-
ure 3(e)), and vascular endothelial growth factor receptor
2 (VEGFR2) (FLK1, 1 : 2000, Santa Cruz, CA) (Figure 3(f)),
but no immunoreaction was found for thyroglobulin (Fig-
ure 3(b)), TTF-1, HBME-1, vascular endothelial growth factor
(VEGF) (VG1, 1 : 20, Dako), VEGFR1 (FLT1, 1 : 1000, Santa
Cruz), and VEGFR3 (FLT4, 1 : 19, Novocastra, Newcastle
upon Tyne, England).
We also screened for mutations in exon 15 of the BRAF
gene as previously described [7], but no mutations were
found in the tissue samples from the hyperplastic thyroid
tissue, follicular carcinoma, papillary microcarcinomas, or
metastatic CCRCC.
3. Discussion
Metastases from nonthyroid malignancies to the thyroid
gland have been reported in 1.4%–3% of all patients who
have surgery for thyroid malignancy, whereas the autopsy
studies report a wide range of prevalences, from 1.9% to
24%, for these metastases to the thyroid [2]. CCRCC has
also been known to present as a metastatic carcinoma of
unknown primary, sometimes discovered in unusual sites
[1, 8] but should be considered in the differential diagnosis of
a thyroid nodule, particularly in patients who have a history
of malignancies [9, 10]. In the present case, the histopatho-
logical examination of the thyroid showed chronic thyroidi-
tis, multinodular hyperplasia, one follicular adenoma, two
papillary microcarcinomas, and multiple foci of metastatic
CCRCC.
Classically, in clinical series, the most common primary
sites of metastasis in the thyroid were kidney, lung, uterus,
and melanoma; however, breast, lung, and skin (melanoma)
were the most common sites of metastases origin in autopsy
series [9–12]. While in autopsy series, metastases to the
thyroid were most often multifocal and variable in size, in
clinical series they were more commonly solitary and could
measure up to 15 cm in diameter [11]. Based on a recent
review of the literature [2], however, the most common
nonthyroid malignancies that metastasize to the thyroid
gland are renal cell (48.1%), colorectal (10.4%), lung (8.3%),
breast carcinomas (7.8%), and sarcomas (4.0%). Curiously,
CCRCC can present as a thyroid mass in the absence of
renal symptoms years or decades after the removal of the
primary tumor [2, 9]. As occurred in our case, metastases to
the thyroid aremore common in women thanmen (female to
male ratio, 1.4 : 1) and in nodular thyroid glands (44.2%) [2].
Although metastasis of “cancer to cancer” (“tumor-to-
tumor,” “tumor-in-tumor,” and “one to another”) is a well-
established phenomenon, occurrence implicating a renal
cancer is rare [13]. Tumor-to-tumor metastasis in thyroid
neoplasms is exceedingly uncommon [14, 15]. In the present
case, the identification of metastatic renal cell carcinoma was
confirmed by the absence of thyroglobulin and TTF-1 in the
neoplastic cells and by the positivity for CD10.
Several studies have indicated that abnormal glands
(nodular goiter, adenomas, well-differentiated carcinomas,
thyroiditis, etc.) are more likely to harbor metastatic disease
than normal glands, presumably due to abnormal blood sup-
ply resulting in decreased oxygen and iodine content [2, 9, 11].
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Figure 3: Tumor-in-tumor. (a and d) Two foci of metastatic renal cell carcinoma presented as central lesions inside hyperplastic adenomatoid
nodules (hematoxylin and eosin). Tumor cells of renal cell carcinoma were negative for thyroglobulin (b) but positive for CD10 (c), EGFR
(e), and VEGFR2 (f).
In rare instances, tumor-in-tumor phenomena reflect tumor-
to-tumor metastases, mainly to follicular adenoma or to
follicular variant of papillary thyroid carcinoma [14]. Primary
papillary thyroid carcinoma can also grow in the core of a
follicular adenoma exhibiting a tumor-in-tumor pattern [16].
An encapsulated thyroid tumor having 3 different concentric
appearances has also been reported recently as another
expression of tumor-in-tumor in the thyroid gland [17]. In
our case, metastatic CCRCC coexisted with papillary thyroid
microcarcinomas, and interestingly, two foci of metastatic
CCRCC were located inside hyperplastic thyroid nodules,
suggesting that the microenvironment in the thyroid nodules
is particularly attractive for renal carcinoma tumor cells.
FNAB of thyroid masses is useful in diagnosis of thyroid
metastases; this, however, requires information about the
nonthyroid malignancies, so that proper antibodies can be
used for immunohistochemical studies [2]. False negatives
with FDG-PET can be explained because some renal tumors
have a low growth rate with low glucose metabolism,
sometimes with differences in the glucose uptake of several
metastases in the same tumo or even due to tumor necrosis.
The discordant PET that results in the present case may be
related to a different pattern in the metastasis or to follicular
cell-derived lesions. To improve the sensitivity and specificity
of FDG-PET in renal cancer, new radiotracers such as choline
are being developed [18].
In our patient, mediastinal metastasectomy was carried
out because the PET showed no tracer uptake elsewhere.
A particularly favorable long-term outcome in selected
patients after metastasectomy with CCRCC has been well
documented in many studies, and an overall 5-year survival
rate of 30–50% is common if isolated metastatic lesions are
resected [19]. EGFR protein overexpression is frequent in
renal cell carcinoma and correlates with the chromosome 7
polysomy and poor prognostic parameters in clear cell renal
cell carcinoma [1, 20]. Sunitinib is an oral receptor tyrosine
kinase inhibitor that targets signaling by PDGFRs, VEGFRs,
and c-kit [21]. In our patient, treatment was started with
sunitinib, and a prolonged survival rate was achieved.
As our case exemplifies, inCCRCCpatients, a particularly
prolonged survival rate may be achieved with the appropriate
therapy, in contrast to the ominous prognosis typically found
in patients with thyroid metastases from other origins. At
the same time, the peculiar distribution of CCRCC foci
inside adenomatoid nodules (tumor-in-tumor) suggests that
the microenvironment in the thyroid nodules is particularly
attractive for renal carcinoma tumor cells.
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